Design and optimization of orally spleen tyrosine kinase (SYK) inhibitors for treatment of solid tumor

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

R. Eric Davis, Vu N. Ngo, Georg Lenz et al. · Nature · 2010 · 1.6K citations · Full text

Medicine, Hematology, Oncology +14

A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival

Anurag Singh, Patricia Greninger, Daniel R. Rhodes et al. · Cancer Cell · 2009 · 864 citations · Full text

Medicine, Cancer Biology, Molecular Biology +14

Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve‐week, randomized, placebo‐controlled trial

Michael E. Weinblatt, Arthur Kavanaugh, Rubén Burgos‐Vargas et al. · Arthritis & Rheumatism · 2008 · 336 citations

Medicine, Immunology, Pharmacology +12

Discovery and SAR of 5-(3-Chlorophenylamino)benzo[<i>c</i>][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer

Fabrice Pierre, Peter Chua, Sean O’Brien et al. · Journal of Medicinal Chemistry · 2010 · 299 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules

Yu Yu, Stéphanie Gaillard, Jude M. Phillip et al. · Cancer Cell · 2015 · 140 citations · Full text

Medicine, Oncology, Pharmacology +12